Syverson Strege & Co’s Takeda Pharmaceutical TAK Stock Holding History

Syverson Strege & Co’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,208	Closed	-$19.9K	–	552
2023 Q1	$19.9K	Buy	+1,208	New	+$19.2K	0.01%	190

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Syverson Strege & Co's TAK Position: Q2 2023 in Review

Syverson Strege & Co sold out of Takeda Pharmaceutical (TAK) in Q2 2023, closing a stake of 1,208 shares — an estimated $19.9K sold.

Syverson Strege & Co first reported a position in TAK in Q1 2023 and held it in 1 quarter. The position peaked at $19.9K in Q1 2023. 310 funds tracked by Wall St. Rank hold TAK as of Q2 2023.

Syverson Strege & Co reported no remaining Takeda Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Syverson Strege & Co sold 1,208 Takeda Pharmaceutical shares in Q2 2023, an estimated $19.9K.
Syverson Strege & Co first reported a position in Takeda Pharmaceutical in Q1 2023 and held it in 1 quarter.
Syverson Strege & Co's Takeda Pharmaceutical position peaked at $19.9K in Q1 2023.
310 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.